CANCER DIAGNOSTICS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Cancer Diagnostics Market - Overview Imaging tests for cancer diagnosis include, ultrasound tests, mammography, MRI scans, CT scan, SPECT imaging, and fluoroscopy imaging. Biopsy procedures include, needle biopsy tests, endoscopic biopsy, and bone marrow biopsy. The global Cancer Diagnostics Market is estimated to account for US$ 45,106.5 Mn in terms of value and is expected to reach US$ 83,641.9 Mn by the end of 2027. Global Cancer Diagnostics Market: Drivers Approval and launch of new approaches is expected to propel growth of the global cancer diagnostics market over the forecast period. For instance, in December 2018, iCAD, Inc. announced U.S. FDA clearance for its deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI. Global Cancer Diagnostics Market: Opportunities Development of diagnostic approaches for various cancer mutations is expected to offer lucrative growth opportunities for players in the global cancer diagnostics market. For instance, in February 2020, QIAGEN N.V launched its FFPE and liquid biopsy PIK3CA diagnostics in Europe as an aid in identifying breast cancer patients with a phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) mutation Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/cancerdiagnostics-market-4029 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Global Cancer Diagnostics Market: Restraints Lack of awareness regarding cancer imaging in emerging economies is expected to limit growth of the market. In developing countries mainly large countries such as India, Brazil, South Africa, and China, it is difficult to reach the rural population for providing healthcare facilities, as there is a lack of adequate streamlining of healthcare infrastructure and skilled medical professionals. In many countries such as Egypt, Saudi Arabia, United Arab Emirates, and others, local women face problem to talk openly about various health issues to male radiologists. Such factors are also expected to limit the market growth. Key Takeaways: The global cancer diagnostics market was valued at US$ 41,542.4 Mn in 2019 and is forecast to reach a value of US$ 83,641.9 Mn by 2027 at a CAGR of 9.2% between 2020 and 2027. Major factor driving the growth of global cancer diagnostics market during the forecast period include high prevalence of cancer, and number of diagnostic options. Biopsy held dominant position in the global cancer diagnostics market in 2019, accounting for 35.1% share in terms of value, followed by Imaging and Tumor Biomarkers Tests, respectively. Biopsy is a highly used cancer diagnostic technique as it involves directly assessing the tumor tissue to identify and monitor progress of the cancer. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/4029 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Market Trends Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in May 2019, EDP Biotech Corporation entered into a non-exclusive agreement with Luminex Corporation to develop, market and sell its blood-based colorectal cancer diagnostic assay, ColoPlex, using Luminex's xMAP Technology. Increasing investment in cancer diagnosis is expected to propel growth of the market. For instance, in September 2019, Kheiron Medical Technologies announced a US$ 22 million Series A round for early breast cancer detection for women worldwide.
Global Cancer Diagnostics Market: Competitive Landscape Major players operating in the global cancer diagnostics market include, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation. Global Cancer Diagnostics Market: Key Developments March 2019: F. Hoffmann-La Roche Ltd. received the U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP142) Assay, as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq (atezolizumab) plus chemotherapy.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/4029 Š Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
Š Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
Š Coherent market Insights. All Rights Reserved